Among 4 analysts covering Marchex (NASDAQ:MCHX), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Marchex had 11 analyst reports since August 6, 2015 according to SRatingsIntel. The stock has “Overweight” rating by Piper Jaffray on Friday, August 28. The firm has “Buy” rating by TH Capital given on Tuesday, December 22. The firm has “Buy” rating given on Tuesday, December 22 by Roth Capital. The firm has “Neutral” rating given on Wednesday, August 10 by Roth Capital. The rating was maintained by RBC Capital Markets on Friday, February 19 with “Outperform”. Piper Jaffray maintained it with “Overweight” rating and $9 target in Friday, August 7 report. As per Tuesday, February 13, the company rating was maintained by Roth Capital. The rating was maintained by RBC Capital Markets with “Outperform” on Thursday, November 5. See Marchex, Inc. (NASDAQ:MCHX) latest ratings:
13/02/2018 Broker: Roth Capital Rating: Hold New Target: $3.4 Maintain
Analysts expect Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) to report $-0.08 EPS on May, 8.They anticipate $0.08 EPS change or 50.00% from last quarter’s $-0.16 EPS. After having $-0.20 EPS previously, Corbus Pharmaceuticals Holdings, Inc.’s analysts see -60.00% EPS growth. The stock decreased 1.97% or $0.12 during the last trading session, reaching $6.22. About 155,473 shares traded. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) has declined 38.80% since April 25, 2017 and is downtrending. It has underperformed by 50.35% the S&P500.
Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. The company has market cap of $355.70 million. The Company’s lead product candidate includes JBT-101, a novel oral endocannabinoid-mimetic drug, which is in Phase 2 clinical trials for the treatment of systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis, and systemic lupus erythematosus diseases. It currently has negative earnings.
Among 5 analysts covering Corbus Pharma (NASDAQ:CRBP), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Corbus Pharma had 21 analyst reports since September 8, 2015 according to SRatingsIntel. Noble Financial maintained the stock with “Buy” rating in Friday, November 10 report. Raymond James initiated the stock with “Buy” rating in Thursday, January 18 report. Cantor Fitzgerald maintained Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) rating on Thursday, October 19. Cantor Fitzgerald has “Buy” rating and $24.0 target. The stock of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) has “Buy” rating given on Monday, February 5 by Noble Financial. Noble Financial maintained the shares of CRBP in report on Saturday, December 23 with “Buy” rating. The firm has “Buy” rating by Aegis Capital given on Monday, March 7. Cantor Fitzgerald maintained it with “Overweight” rating and $24 target in Thursday, March 30 report. The rating was maintained by Noble Financial with “Buy” on Tuesday, August 8. The firm has “Buy” rating given on Tuesday, June 13 by Cantor Fitzgerald. As per Monday, January 29, the company rating was maintained by Cantor Fitzgerald.
Since February 5, 2018, it had 6 buys, and 0 sales for $1.26 million activity. $189,845 worth of Marchex, Inc. (NASDAQ:MCHX) was bought by Edenbrook Capital – LLC.
Marchex, Inc. operates as a mobile advertising analytics company. The company has market cap of $118.99 million. The Company’s products include Marchex Call Analytics, an analytics technology platform that provides data and insights to measure the performance of mobile, online, and offline advertising for advertisers and small business resellers; and Marchex Search Analytics, a product for search marketers that drive phone calls from search campaigns, as well as attributes inbound phone calls made directly from paid search ads and landing pages to a keyword. It currently has negative earnings. The firm also provides Marchex Display and Video Analytics, a product for marketers that buy digital display advertising, as well as measures the influence that display advertising has on inbound phone calls; Marchex Social Analytics, a product for marketers that buy social media advertising; and Marchex Call Marketplace, a mobile advertising network for businesses that depend on inbound phone calls to drive sales, as well as offer advertisers ad placements across various mobile and online media sources to deliver qualified calls to their businesses.
Investors sentiment increased to 1.38 in 2017 Q4. Its up 0.46, from 0.92 in 2017Q3. It increased, as 5 investors sold Marchex, Inc. shares while 19 reduced holdings. 14 funds opened positions while 19 raised stakes. 19.71 million shares or 4.96% less from 20.74 million shares in 2017Q3 were reported. Invesco Limited reported 89,545 shares. Tudor Inv Et Al has 0% invested in Marchex, Inc. (NASDAQ:MCHX). Geode Cap Ltd Com has 164,240 shares for 0% of their portfolio. Parallax Volatility Advisers Ltd Partnership holds 0% or 10,468 shares. Winslow Asset Mgmt Inc has invested 0.65% in Marchex, Inc. (NASDAQ:MCHX). Pnc Financial Services Gp reported 0% in Marchex, Inc. (NASDAQ:MCHX). Synovus Fin Corporation reported 174,277 shares or 0.01% of all its holdings. Moreover, Tower Cap Ltd Llc (Trc) has 0.02% invested in Marchex, Inc. (NASDAQ:MCHX) for 42,625 shares. Paw Cap stated it has 4.06% of its portfolio in Marchex, Inc. (NASDAQ:MCHX). Millennium Management Limited Com reported 269,792 shares. 655 are held by Howe And Rusling. Bridgeway Cap holds 0% or 127,000 shares. Stone Ridge Asset Management Limited Liability Co holds 0.01% of its portfolio in Marchex, Inc. (NASDAQ:MCHX) for 44,642 shares. Public Employees Retirement Sys Of Ohio holds 136,694 shares. United Kingdom-based Glg Prtn Limited Partnership has invested 0% in Marchex, Inc. (NASDAQ:MCHX).